39 related articles for article (PubMed ID: 23535072)
1. Targeting PAK4 Inhibits Ras-Mediated Signaling and Multiple Oncogenic Pathways in High-Risk Rhabdomyosarcoma.
Dasgupta A; Sierra L; Tsang SV; Kurenbekova L; Patel T; Rajapakse K; Shuck RL; Rainusso N; Landesman Y; Unger T; Coarfa C; Yustein JT
Cancer Res; 2021 Jan; 81(1):199-212. PubMed ID: 33168646
[TBL] [Abstract][Full Text] [Related]
2. The Circulating Transcriptome as a Source of Biomarkers for Melanoma.
Solé C; Tramonti D; Schramm M; Goicoechea I; Armesto M; Hernandez LI; Manterola L; Fernandez-Mercado M; Mujika K; Tuneu A; Jaka A; Tellaetxe M; Friedländer MR; Estivill X; Piazza P; Ortiz-Romero PL; Middleton MR; Lawrie CH
Cancers (Basel); 2019 Jan; 11(1):. PubMed ID: 30634628
[TBL] [Abstract][Full Text] [Related]
3. A novel compound which sensitizes BRAF wild-type melanoma cells to vemurafenib in a TRIM16-dependent manner.
Sutton SK; Carter DR; Kim P; Tan O; Arndt GM; Zhang XD; Baell J; Noll BD; Wang S; Kumar N; McArthur GA; Cheung BB; Marshall GM
Oncotarget; 2016 Aug; 7(32):52166-52178. PubMed ID: 27447557
[TBL] [Abstract][Full Text] [Related]
4. P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma.
Ong CC; Jubb AM; Jakubiak D; Zhou W; Rudolph J; Haverty PM; Kowanetz M; Yan Y; Tremayne J; Lisle R; Harris AL; Friedman LS; Belvin M; Middleton MR; Blackwood EM; Koeppen H; Hoeflich KP
J Natl Cancer Inst; 2013 May; 105(9):606-7. PubMed ID: 23535073
[TBL] [Abstract][Full Text] [Related]
5. PAK1 and Therapy Resistance in Melanoma.
Kichina JV; Maslov A; Kandel ES
Cells; 2023 Sep; 12(19):. PubMed ID: 37830586
[TBL] [Abstract][Full Text] [Related]
6. Targeting NRAS in melanoma.
Kelleher FC; McArthur GA
Cancer J; 2012; 18(2):132-6. PubMed ID: 22453013
[TBL] [Abstract][Full Text] [Related]
7. [New therapies targeting the genetic mutations responsible for different types of melanoma].
Botella-Estrada R; Sanmartín Jiménez O
Actas Dermosifiliogr; 2010 Jun; 101(5):394-400. PubMed ID: 20525481
[TBL] [Abstract][Full Text] [Related]
8. PAK1 overexpression promotes cell proliferation in cutaneous T cell lymphoma via suppression of PUMA and p21.
Wang Y; Gu X; Li W; Zhang Q; Zhang C
J Dermatol Sci; 2018 Apr; 90(1):60-67. PubMed ID: 29307600
[TBL] [Abstract][Full Text] [Related]
9. Taming the wild-types: targeting PAK1 in melanomas that lack BRAF mutations.
Smalley KS; Weber JS
J Natl Cancer Inst; 2013 May; 105(9):591-2. PubMed ID: 23535072
[No Abstract] [Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
